Home >> Antibodies >> Carboxypeptidase A1 / CPA1 (Pancreatic Cancer Marker)

Carboxypeptidase A1 / CPA1 (Pancreatic Cancer Marker)

Recombinant Mouse Monoclonal Antibody [Clone rCPA1/8688]

Printable

Key References

Bioinformatics

Catalog #

Size

20 ug

100 ug

Price (USD)

219.00

499.00

Formulation

Purified Ab with BSA and Azide at 200ug/ml

Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Performance Guarantee

Catalog No

Size

20 ug

100 ug

Formulation

Purified Ab with BSA and Azide at 200ug/ml

Purified Ab WITHOUT BSA and Azide at 1.0mg/ml

Price (USD)

219.00

499.00

Printable

Key References

Bioinformatics

Product Details

Synonyms

Carboxypeptidase A1 (pancreatic); CPA1; Pancreatic Carboxypeptidase A1; Procarboxypeptidase A1 pancreatic

Positive Control

Pancreas.

Known Applications & Suggested Dilutions

Western Blot, IHC-P More Details

Western Blot (1-2ug/ml)
Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT)
(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes)
Optimal dilution for a specific application should be determined.

Immunogen

Recombinant full-length human CPA1 protein

Cellular Localization

Secreted.

Species Reactivity

Human.

Host / Ig Isotype

Mouse / IgG1, kappa

Mol. Weight of Antigen

47kDa

Specificity & Comments

Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.